^131Ⅰ-肿瘤细胞核人鼠嵌合抗体放射免疫治疗中晚期肺癌的近期疗效及核素显像观察

Short-term effect of Iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer and the observation of radionuclide imaging

目的观察^131Ⅰ-肿瘤细胞核人鼠嵌合单克隆抗体（^131Ⅰ-chTNT）放射免疫治疗中晚期肺癌的疗效。方法15例确诊的中晚期肺癌患者，通过静脉注射^131Ⅰ-chTNT进行治疗，并于治疗后1、3、5、7、9、15d行动态核素显像，以客观反应率（ORR）来评估疗效。结果完全反应者（CR）1例，部分反应者（PR）5例，7例无变化（NC），2例出现病情进展（PD），客观反应率为40％（完全反应＋部分反应）。核素显像显示，^131Ⅰ-chTNT能在较长时间内稳定地分布在肺肿瘤病灶处。主要的副作用为轻度的和可逆的骨髓抑制。结论^131Ⅰ-chTNT治疗中晚期肺癌近期疗效良好，治疗后动态放射性核素显像可客观显示病灶放射性摄取情况。

Objective To assess the therapeutic efficacy of Iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy（^131Ⅰ-ehTNT） in patients with advanced lung cancer. Methods 15 patients confirmed diagnosis of advanced lung cancer were treated with intravenous injections of ^131Ⅰ-chTNT, and radionuclide imaging was performed at 1,3,5,7,9,15 day after therapy, the objective response rate（ORR） was used to assess the therapeutic efficacy. Results The results showed an ORR of 40% （ complete response, 1 case ; partial response,5 cases ; no change, 7 cases ; and progressive disease, 2 cases） ; radionuelide imaging study demonstrated that ^131Ⅰ-chTNT had a long and stable retention in lung tumor. The most obvious adverse side effect was mild and reversible bone marrow suppression. Conclusion The short-term effect of ^131Ⅰ-chTNT in patients with advanced lung cancer is good, radionuclide imaging after therapy can objectively show localization of the radioactivity in tumors